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Abstract
Chronic hepatitis C virus (HCV) infection is a leading cause of liver disease. Liver inflammation underlies infection-induced
fibrosis, cirrhosis and liver cancer but the processes that promote hepatic inflammation by HCV are not defined. We provide
a systems biology analysis with multiple lines of evidence to indicate that interleukin-1b (IL-1b) production by intrahepatic
macrophages confers liver inflammation through HCV-induced inflammasome signaling. Chronic hepatitis C patients
exhibited elevated levels of serum IL-1b compared to healthy controls. Immunohistochemical analysis of healthy control
and chronic hepatitis C liver sections revealed that Kupffer cells, resident hepatic macrophages, are the primary cellular
source of hepatic IL-1b during HCV infection. Accordingly, we found that both blood monocyte-derived primary human
macrophages, and Kupffer cells recovered from normal donor liver, produce IL-1b after HCV exposure. Using the THP-1
macrophage cell-culture model, we found that HCV drives a rapid but transient caspase-1 activation to stimulate IL-1b
secretion. HCV can enter macrophages through non-CD81 mediated phagocytic uptake that is independent of productive
infection. Viral RNA triggers MyD88-mediated TLR7 signaling to induce IL-1b mRNA expression. HCV uptake concomitantly
induces a potassium efflux that activates the NLRP3 inflammasome for IL-1b processing and secretion. RNA sequencing
analysis comparing THP1 cells and chronic hepatitis C patient liver demonstrates that viral engagement of the NLRP3
inflammasome stimulates IL-1b production to drive proinflammatory cytokine, chemokine, and immune-regulatory gene
expression networks linked with HCV disease severity. These studies identify intrahepatic IL-1b production as a central
feature of liver inflammation during HCV infection. Thus, strategies to suppress NLRP3 or IL-1b activity could offer
therapeutic actions to reduce hepatic inflammation and mitigate disease.
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Introduction
Chronic inflammation is a major contributor to disease and is
the basis of hepatitis C virus (HCV)-mediated liver damage. HCV
is a hepatotropic, enveloped virus that carries a single-stranded
positive-sense RNA genome, and chronically infects nearly 3% of
the world’s population [1]. HCV productively infects hepatocytes
to induce liver inflammation and progressive tissue damage
leading to fibrosis and cirrhosis. These processes underlie liver
dysfunction and are thought to drive the onset of liver cancer [2,3].
However, the molecular mechanism(s) by which HCV stimulates
hepatic inflammation are not defined. Interleukin-1b (IL-1b)i sa
central component of the cytokine milieu that accompanies both
acute and chronic inflammation and viral disease [4,5]. During
microbial infection, IL-1b production is induced by cellular
sensing of pathogen-associated molecular pattern (PAMP) [6,7]
motifs within microbial macromolecules and/or by metabolic
products that accumulate from infection. Production of active IL-
1b requires two signals, ‘‘signal one’’ to activate NF-kBi n
stimulated cells and induce IL-1b mRNA expression, and ‘‘signal
two’’ to activate a Nod-like receptor (NLR) to promote
downstream caspase-1 cleavage and processing of proIL-1b into
a biologically active, secreted cytokine [8,9]. Virus infection has
been shown to induce IL-1b production through inflammasome
signaling [10]. In particular, flavivirus agents related to HCV,
including West Nile virus and Japanese encephalitis virus, trigger
IL-1b production through the NLRP3 inflammasome to render
immune regulation [11,12]. Though the spectrum of IL-1b
responsive genes within the liver has not been defined, IL-1b is
thought to mediate its inflammatory actions by inducing the
expression of proinflammatory genes, recruiting immune cells to
the site of infection, and by modulating infiltrating cellular
PLOS Pathogens | www.plospathogens.org 1 April 2013 | Volume 9 | Issue 4 | e1003330immune-effector actions [4,13]. As a pleiotropic inflammatory
factor, IL-1b has also been implicated in promoting tissue
pathology and inducing the production of profibrogenic mediators
[14–17], thereby underscoring its potential role in HCV disease.
HCV is a human blood-borne virus, of which acute exposure
most often progresses to chronic infection [18] during which
persistent viremia reaches levels greater than 10
6 viral genome
equivalents/cc blood in many patients [18,19]. The unique
architecture of the liver, in which blocks of hepatocytes are
separated by spaces or ‘‘sinusoids’’ that support blood flow and
dispersion of metabolites, facilitates viremia while serving to
constantly expose resident hepatic cells and blood and liver-
infiltrating myeloid cells to the virus. In infected hepatocytes, viral
RNA recognition by retinoic acid inducible gene-I (RIG-I), the
essential pathogen recognition receptor (PRR) of HCV infection
[20], signals innate immune-dependent activation of transcription
factors to induce type 1 interferon (IFN) and the expression of
interferon-stimulated genes (ISGs) that suppress viral replication.
However, HCV evades hepatocyte innate immunity through the
actions of the viral NS3/4A protease that targets and cleaves
mitochondrial antiviral signaling protein (MAVS) also known as
IPS-1 (herein referred to as MAVS), the adaptor protein of RIG-I
signaling; thus disrupting innate immunity and promoting chronic
infection [21]. Moreover, exposure of hepatic stellate cells to
HCV, viral antigens, or inflammatory signals can induce their
fibrogenic activity to promote liver damage [22], whereas HCV
exposure of hepatic myeloid cells, including resident macrophag-
es/Kupffer cells and dendritic cells, induces cell activation to
promote immune response regulation [23,24]. In particular,
Kupffer cells, the intrahepatic macrophages, play critical roles in
microbial surveillance in which constant phagocytic uptake of
macromolecules from hepatic sinusoidal blood provides the means
for liver-wide pathogen detection. Kupffer cells account for
approximately 15% of the total liver cell population [25].
Importantly, Kupffer cells can internalize HCV through a process
of phagocytosis wherein internalized viral products can induce
innate immune signaling of IFN-b expression [26]. This process
might also induce proinflammatory cytokines that serve to recruit
immune cells to the site of infection, thus supporting immune-
mediated liver damage characteristic of chronic hepatitis C.
Defining the mechanisms of hepatic inflammation induction by
HCV is paramount for establishing attractive approaches to
minimize HCV-related liver disease.
In this report we reveal a linkage of hepatic inflammation and
disease in chronic hepatitis C patients attributed to IL-1b
production by liver macrophages. Our observations define the
hepatic macrophage/HCV interface and IL-1b production
through the NLRP3 inflammasome as critical features underlying
liver disease in chronic HCV infection.
Results
IL-1b associates with hepatic disease and is produced by
liver macrophages in chronic hepatitis C patients
To assess hepatic gene expression patterns and host response
processes associated with liver disease in chronic HCV infection,
we conducted a systems biology analysis of the host response to
HCV infection that included high-throughput transcriptional
profiling of human liver coupled with in vitro modeling of the
HCV/host interface. We first performed global transcriptome
analysis using RNA-sequencing (RNA-seq) of RNA recovered
from liver biopsies of normal control (donor) or chronic HCV-
infected livers of patients staged according to mild (mild
inflammation and no fibrosis) or severe (cirrhosis undergoing liver
transplantation) disease. The initial comparison of transcriptome
profiles from control and HCV patient liver identified four major
gene expression patterns that differentially associated with liver
disease (Figure 1A and Table S1). These analyses determined
that cytokine/cytokine receptor interaction and chemokine
signaling pathways were the most highly represented with 158
differentially expressed genes (.1.5-fold change and false discov-
ery rate (FDR) 0.05). HCV patient liver displayed induced
expression of a variety of immunomodulatory gene products
known to associate with the inflammatory responses, including
OSM, IL-6, IL-8, and TGF-b (Group 3, Figure 1A). Impor-
tantly, expression of IL-1b, a key proinflammatory cytokine,
generally associated with HCV infection and the onset of liver
disease. Moreover, assessment of a subset of genes expressed
(Group 2 and Group 3, Figure 1A) in cells directly treated with
IL-1b confirmed that a range of proinflammatory cytokines,
chemokines, and signaling factors are directly induced by IL-1b
(Figure S1). Thus, IL-1b and IL-1b–responsive proinflammatory
cytokine expression associates with HCV infection and liver
disease severity. To assess whether circulating IL-1b can be
detected during chronic HCV infection, we evaluated serum levels
of IL-1b from both chronic hepatitis C patients and healthy
controls. IL-1b levels were significantly higher in individuals with
chronic hepatitis C and revealed a possible linkage of increasing
IL-1b with liver fibrosis, suggesting involvement of IL-1b with
HCV disease (Figure 1B). We also assessed whether hepatocytes
are the primary source of hepatic IL-1b during chronic HCV
infection. Surprisingly, we found that upon either HCV exposure
or infection neither immortalized primary human hepatocytes
(PH5CH8 and IHH cells) nor hepatoma cells (Huh7) expressed
inducible IL-1b mRNA or secreted appreciable levels of mature
IL-1b (Figure S2A, S2B). To identify the cellular source of
hepatic IL-1b during chronic HCV infection, we conducted
confocal microscopy analysis of immunostained liver sections from
normal donor liver or patients with chronic hepatitis C. Liver
sections were co-stained with anti- IL-1b and anti-CD68, a surface
Author Summary
Hepatitis C virus (HCV) causes chronic infection of the liver
and is a leading cause of liver inflammation, cirrhosis and
liver cancer in nearly 200 million people worldwide.
Importantly, hepatic inflammation during chronic HCV
infection is considered to be the primary catalyst for
progressive liver disease and development of liver cancer.
However, the underlying molecular mechanism(s) of HCV-
mediated hepatic inflammation are not well understood.
The goal of this study was to determine the mechanisms of
HCV-induced inflammation. We found that serum IL-1b
levels are elevated in chronic hepatitis C patients.
Furthermore, we found that hepatic macrophages or
Kupffer cells are the major IL-1b-producing cell population
within HCV infected livers. Our studies, using the THP1 cell
culture model of HCV exposure, reveal that exposure of
macrophages to HCV induces IL-1b through a process of
infection-independent phagocytic virus uptake that trig-
gers signaling through MyD88/TLR7 and NLRP3 inflamma-
some pathways to drive IL-1b expression and maturation/
secretion, respectively. RNA sequencing (RNA-seq) analysis
of patient liver biopsies shows that viral triggering of these
signaling pathways drives an inflammatory response linked
with liver disease in patients with chronic hepatitis C. Our
results identify HCV-induced IL-1b production by hepatic
macrophages as a critical and central process that
promotes liver inflammation and disease.
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Kupffer cells. We found that while CD68-negative cell popula-
tions, including hepatocytes, contained little or no IL-1b, liver
macrophages from chronic hepatitis C patients expressed IL-1b,
and CD68-positive cells were present at increased frequency
compared with healthy controls (Figure 1C and Figure S3).
Thus, IL-1b associates with chronic HCV infection, and our
observations identify Kupffer cells and/or infiltrating liver
macrophages but not hepatocytes as a primary hepatic source of
IL-1b.
HCV stimulates IL-1b production upon uptake by
macrophages
To assess the contribution of hepatic macrophages to the
production of IL-1b from HCV exposure, we first modeled HCV
exposure of macrophages in culture using primary human blood
monocyte-derived macrophages. Primary macrophages express
IL-1b mRNA and secrete IL-1b upon exposure to HCV ex vivo
(Figure 2A). Neither Kupffer cells nor macrophages in general
are known to be productively infected with HCV [27], though in
the liver they are constantly exposed to the virus through liver
sinusoidal blood flow wherein exposure to HCV might trigger
their production of IL-1b. To test this possibility, we collected
mononuclear cells from saline wash-out of normal donor liver and
treated the cells with conditioned cell culture media (mock) or
media containing UV-inactivated HCV. Cells were then stained
with specific antibodies to detect intracellular IL-1b and mono-
cyte/macrophage cell surface markers (CD14 and CD68). We
found that all CD68+ cells recovered from donor liver also
expressed CD14, thus defining them as hepatic macrophages (data
not shown). Flow cytometric analysis of these cells demonstrated
that HCV exposure induced IL-1b production (Figure 2B and
Figure S4A, S4B). As UV-inactivated HCV does not replicate,
these observations suggest that hepatic macrophages can produce
IL-1b after HCV exposure in a manner independent of direct cell
Figure 1. IL-1b associates with hepatic disease and is produced by liver macrophages in chronic hepatitis C patients. (A) Hierarchical
clustering of differentially expressed genes as determined by RNA-seq analysis of liver specimens from control or HCV patients with mild (no fibrosis)
and severe (cirrhosis) liver disease. Clustering analysis of a total of 158 differentially expressed genes (.1.5-fold change and FDR, 0.05) in the
cytokine-cytokine receptor and chemokine signaling pathways is shown. The expression of group-3 genes were increased only in patients with severe
liver disease; Group-3 genes and the expression key are shown at the right (for full description, see Table S1). For analysis see methods. (B) IL-1b levels
from sera of chronic hepatitis C patients and healthy controls. (C) Immunohistochemical staining and confocal microscopy analysis of healthy liver
and chronic hepatitis C patient liver samples. CD68 marks macrophages (Kupffer cells or infiltrating macrophages) (red), IL-1b (green), and DRAQ5
(blue) stains the nuclei. A quantification plot of CD68+IL-1b+ cells and CD68+IL-1b - of the total IL-1b+ cells is depicted from chronically infected
(three patients,) and normal healthy liver samples. The area within the white box of the far right merged panel is enlarged and shown with cell
frequency counts at right. **P=0.0062 and ***p,0.0001 by student’s t-test. Arrows (white) indicate hepatocytes adjacent to CD68+/IL-1b+ Kupffer
cells (yellow arrows).
doi:10.1371/journal.ppat.1003330.g001
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can drive IL-1b production from macrophages. Using an in vitro
model of macrophage exposure to HCV based on differentiated
human THP-1 cells, we found that as in primary macrophages,
exposure of THP-1 cells to HCV stimulates the expression of IL-
1b mRNA that peaks 3 hr after virus exposure (Figure 2C),
leading to secretion of mature IL-1b (Figure 2D). THP-1 cell
exposure to HCV triggers a rapid, transient activation and
cleavage of caspase-1, which coincides with the production
(Figure 2E) and secretion (Figure 2F) of mature IL-1b. Neither
the production nor secretion of IL-1b were observed in parallel
cultures of resting cells not exposed to HCV (data not shown). To
address the possibility that contaminants from the HCV prepa-
ration might trigger IL-1b production and secretion, we purified
HCV virions through a sucrose cushion prior to cell treatment.
Both HCV-containing media and the resulting purified virions
were infectious in Huh7 cells (Figure S5). We found that purified
HCV virions stimulate IL-1b secretion in a manner comparable to
IL-1b induction triggered by treatment of cells with HCV-
containing supernatants (Figure 2G), thus demonstrating the
HCV virion-specific activity of IL-1b production in macrophages.
As myeloid cells do not support HCV replication [27], we
investigated how HCV virions might trigger IL-1b expression.
HCV binds and enters hepatocytes through engagement of cell
surface CD81, followed by association with additional co-receptor
molecules [28]. However, we found that following virus exposure,
HCV RNA is present in THP1 cells through a process
independent of the CD81 co-receptor, demonstrating that the
virus is not entering THP-1 cells via an active entry mechanism
(Figure S6A). We therefore evaluated the role of phagocytosis in
THP1 cell uptake of HCV by examining virus uptake after cell
treatment with cytochalasin D (an inhibitor of phagocytosis) or the
vacuolar type H+-ATPase inhibitor bafilomycin (which prevents
endosome acidification). Exposure of THP-1 cells to HCV in the
presence of cytochalasin D but not bafilomycin suppressed virus
uptake as measured by intracellular accumulation of HCV RNA
(Figure S6B), while treatment of cells with either inhibitor caused
a significant reduction in HCV-induced IL-1b mRNA expression
(Figure 2H). We also confirmed in the THP-1 model that the IL-
1b-stimulatory activity of HCV did not require viral replication, as
UV-inactivated virus induced robust IL-1b production from
treated THP-1 cells as effectively as infectious HCV (Figure 2I).
Thus, both infection-independent phagocytic-mediated uptake of
HCV virions as well as endosomal acidification are involved in IL-
1b stimulation in macrophages.
HCV stimulates IL-1b expression through MyD88-
dependent viral RNA signaling by Toll-like receptor (TLR) 7
To determine how HCV triggers IL-1b production in
macrophages, we assessed the requirement for known PRRs in
the activation of IL-1b expression. We first examined the
requirement for MAVS or myeloid differentiation primary
response gene 88 (MyD88)-dependent innate immune signaling
in IL-1b expression. Whereas stable knockdown of MyD88
abrogated HCV-induced IL-1b mRNA induction and proIL-1b
production, knockdown of MAVS had no effect on IL-1b mRNA
expression (Figure 3A, B and Figure S7A, S7B). In contrast to a
role for MyD88 in activation of signal one of inflammasome
activation and IL-1b production, neither MyD88 nor MAVS were
required for signal two that drives caspase-1 activation for
processing IL-1b into its active, secreted form (Figure 3C). We
next sought to identify the HCV component(s) that trigger IL-1b
expression. Previous studies have shown that macrophage
exposure to viral products can trigger IL-1b production [29]
and that HCV RNA itself is a potent PAMP that triggers host
innate immune response programs [20,30]. We therefore evalu-
ated the ability of the HCV RNA to trigger IL-1b expression in
THP1 cells. We found that transfected but not extracellular HCV
RNA is sufficient to stimulate both IFN-b and IL-1b mRNA
expression (Figure 3D). By comparison, transfected synthetic
double-stranded RNA, poly inosine-cytosine (polyIC), also triggers
strong IFN-b mRNA expression. However, despite comparable
levels of IFN induced by both polyIC and HCV, HCV RNA was a
much greater stimulant of IL-1b, thus demonstrating that HCV
RNA is a highly potent and specific agonist of IL-1b mRNA
induction.
To define the HCV viral-RNA moiety and host PRR that drives
IL-1b mRNA induction, we stimulated cells with either the HCV
RNA polyU/UC region (PAMP) or the non-stimulatory X-region
of the viral RNA. The HCV RNA polyU/UC region is a uridine-
rich motif within the 39 nontranslated region of HCV genome that
exhibits potent activation of type I IFN and has thus been defined
as a viral PAMP for RIG-I activation [30,31]. In contrast, the
HCV RNA X-region is located in the 39 nontranslated region of
the viral genome and lacks the ability to stimulate type I IFN [30].
We found that the polyU/UC but not the X-region RNA motif
was sufficient to trigger IL-1b mRNA expression when introduced
into THP1 cells (Figure 3E). Remarkably, IL-1b and IFN-b
mRNA are induced through MyD88 or MAVS-dependent
signaling, respectively, in response to HCV RNA in macrophages
(Figure 3F), with both exhibiting dose dependence of polyU/UC
motif concentration (Figure 3G, and see Figure 3A). Thus, the
polyU/UC PAMP motif within the HCV RNA is a non-self ligand
of PRR signaling through which MyD88-dependent signals impart
IL-1b mRNA expression while RIG-I/MAVS signaling drives
IFN-b expression. We also assessed how MyD88 induction of IL-
1b is propagated in the context of HCV stimulation. Notably,
TLR7 resides within endosomes and can recognize uridine-rich,
single-stranded RNA as a PAMP to signal through MyD88
[32,33]. Moreover, TLR7 is abundantly expressed in tissue
macrophages and differentiated THP1 cells [34]. As bafilomycin
treatment abrogates IL-1b expression induced by HCV (see
Figure 2G), signaling from endosomal TLRs is likely important
for inflammasome triggering. We therefore examined the require-
ment for TLR7 in HCV RNA-induced IL-1b mRNA expression.
Knockdown of TLR7 expression significantly reduced signaling of
IL-1b mRNA expression triggered by cell exposure to HCV
(Figure S8A and S8B) or induced by HCV RNA (Figure 3H).
Thus, ‘‘signal one’’ of inflammasome activation is mediated by
TLR7 recognition of HCV RNA within endosomes to induce IL-
1b mRNA expression through MyD88-dependent signaling upon
macrophage exposure to HCV.
The NLRP3 inflammasome and potassium efflux are
required for HCV-driven maturation of IL-1b in
macrophages
Comparison of proIL-1b processing in cells stimulated with
HCV RNA or HCV itself demonstrated that secretion of IL-1b
requires events triggered upon uptake of intact virus (Figure 4A),
indicating that HCV must also induce the ‘‘signal two’’ that
mediates full activation of the inflammasome leading to IL-1b
secretion. To define the inflammasome responsible for IL-1b
processing triggered by HCV, we examined the requirement for
specific NLR signaling in IL-1b secretion. In particular, the
NLRP3 inflammasome has been shown to respond to diverse
stimuli, including virus infection [10], and drives proIL-1b
processing during flavivirus infection [11,12]. We therefore assessed
IL-1b production in THP-1 cells stably expressing non-targeting
HCV Induction of Interleukin-1b
PLOS Pathogens | www.plospathogens.org 4 April 2013 | Volume 9 | Issue 4 | e1003330shRNA or shRNA targeting caspase-1 or NLRP3. IL-1b mRNA
expression was efficiently induced by HCV regardless of caspase-1
or NLRP3 knockdown (Figure 4B and Figure S9A, S9B), but
processing of proIL-1b to its active form in response to virus was
completely abolished upon loss of caspase-1 or NLRP3
(Figure 4C); implicating that NLRP3 and caspase-1 mediate
HCV-induced IL-1b maturation. Consistent with this observation,
expression knockdown of ASC, the essential NLRP3 signaling-
adaptor protein [35], similarly abrogated the processing of IL-1b
(Figure 4C and Figure S9C). Thus, HCV induces the
maturation of proIL-1b in macrophages through activation of
the NLRP3 inflammasome.
HCV products have been shown to induce reactive oxygen
species (ROS), while products of virus infection have been shown
Figure 2. HCV stimulates IL-1b production upon uptake by macrophages. (A) IL-1b mRNA expression (upper panel) and secreted IL-1b
protein levels (lower panel) from primary monocyte-derived macrophages of healthy human donor blood. Cells were mock-treated or treated with
infectious HCV supernatant (moi=0.01 based on Huh7 focus forming units (ffu) or treated with 1 mg/ml of LPS and ATP 5 mM (LPS/ATP; positive
control). (B) Intracellular cytokine staining of treated CD14+ cells recovered from saline washout of healthy donor liver. Cells were left untreated
(unstim) or were cultured with conditioned media (mock, negative control), LPS (positive control) or treated with UV-inactivated HCV (moi=0.01
based on Huh7 focus forming units (ffu)). Data are shown from one donor and are representative two experiments each of cells collected from two
independent donors. In the analysis shown the frequency of IL-1b-expressing cells was: unstim, 2.7%; mock, 6.4%; LPS, 76.5%; UV-HCV. 67.6%. (C)–(I)
Analysis of THP1 cells. (C) IL-1b mRNA expression post exposure to HCV. (D) IL-1b protein secretion after treatment with variable doses of HCV
(moi=0.001, 0.01 or 0.1 Huh7 ffu) or LPS/ATP at 1 mg/ml for 24 hr. (E) Immunoblot showing the kinetics of caspase-1 activation after HCV exposure.
(F) Levels of secreted IL-1b over a time course after HCV exposure (moi=0.01 based on Huh7 ffu). (G) IL-1b levels secreted 24 hr after exposure to
(left to right) cell culture media, sucrose solution, sucrose-purified culture media, infectious HCV supernatant or sucrose-purified HCV virions.( H) IL-1b
mRNA expression in pre-treated with DMSO (control), bafilomycin (2.5 uM) or cytochalasin D (10 mM) cells and exposed to media or infectious HCV
supernatant (moi=0.01 Huh7 ffu). (I) Levels of secreted IL-1b 24 hr post treatment with conditioned media alone (mock) or treatment with live
infectious HCV (HCV, moi=0.01) or UV-inactivated HCV (HCV-UV). *P=0.0175 and ***P=0.0005, by student t-test.
doi:10.1371/journal.ppat.1003330.g002
HCV Induction of Interleukin-1b
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intracellular ion flux and pH change, each of which are implicated
as cellular metabolic changes that induce the assembly of the
NLRP3 inflammasome [36–39]. To define the virus-induced
metabolic changes that might impart NLRP3 inflammasome
activation upon cellular uptake of HCV, we pretreated cells with
diphenyleneiodonium (DPI, ROS inhibitor) or glybenclamide
(Glyben, inhibitor of potassium channels) and assessed processing
of IL-1b. While ROS inhibition only affected IL-1b processing
induced by HCV at high doses (Figure S10), IL-1b maturation
was blocked in a dose-dependent manner by glyben treatment of
cells (Figure 4D), implicating HCV-induced potassium efflux
as a trigger of the NLRP3 inflammasome. Consistent with this
notion, IL-1b maturation was blocked when cells were cultured
in isotonic media containing 100 mM KCL to prevent
intracellular potassium depletion while culturing in isotonic
N a C lm e d i ad i dn o ta l t e rH C V - i n d u c e dI L - 1 b maturation
(Figure 4E). These results reveal a conserved process of virus-
induced inflammatory signaling in which HCV induction of
potassium efflux leads to NLRP3 inflammasome activation.
Figure 3. HCV stimulation of IL-1b expression occurs through MyD88-dependent viral RNA signaling by TLR7. (A) THP1 cells stably
expressing non-targeting shRNA (control) or shRNA specific to MAVS or MyD88 were mock treated with media alone, exposed to HCV (moi=0.01) or
treated with LPS (1 mg/ml) and IL-1b expression assessed by qRT-PCR, *P=0.0341and *P=0.013.( B) Immunoblot analysis of IL-1b in THP-1 stably
expressing the indicated shRNA. Cells were exposed to media alone (M) or infectious HCV supernatant for 6 hr. (C) Immunoblot of caspase-1 in THP-1
stably expressing the indicated shRNA. (D) IL-1b (upper panel) and IFN-b (lower panel) mRNA expression in THP-1 post-treatment with transfection
reagent alone (control) or transfected with full length HCV RNA or poly IC (transfected); or treated with media containing full length HCV RNA or poly
IC (extracellular). (E) IL-1b mRNA levels in THP-1 transfected with HCV polyU/UC RNA (1 mg/ml), HCV X-region (1 mg/ml) or exposed to infectious HCV
for 6 hrs. (F) IL-1b (upper panel) and IFN-b (lower panel) mRNA expression in THP1 harboring the indicated shRNA, *P=0. 0115, **P=0.0094 and
***P=0.0009.( G) IL-1b (upper panel) and IFN-b (lower panel) mRNA expression in THP-1 cells transfected with increasing doses (0.125, 0.25, 0.5, 1 and
2 mg/ml) of HCV polyU/UC RNA. (H) IL-1b mRNA expression in THP1 cells stably expressing non-targeting or shRNA specific to TLR7, *P=0.022,b y
student’s t-test.
doi:10.1371/journal.ppat.1003330.g003
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expression with subsequent NLRP3 activation triggered by
virus-induced potassium efflux as the mediators of HCV-
induced IL-1b production in macrophages.
Macrophage exposure to HCV induces inflammasome
signaling of IL-1b and proinflammatory cytokine and
chemokine expression
Our study identifies macrophage-produced IL-1b induced by
cell exposure to HCV as a central component initiating the
inflammatory response linked with HCV pathogenesis, in which
IL-1b produced by macrophages transmits an IL-1b-driven
inflammatory response globally within liver tissue. To ascertain
how initial inflammasome signaling in macrophages propagates
into a hepatic inflammatory response, we conducted a direct
comparative RNA-seq analysis of gene expression datasets from
chronic hepatitis C patients to the RNA-seq transcriptome of
THP1 cells during an acute time course after exposure to HCV.
The comparison identified a bioset of commonly induced genes in
the two most highly represented pathways, cytokine-cytokine
receptor signaling, and chemokine signaling, of which a subset of
genes associated with severe liver disease in HCV patients,
including IL-1b and IL-1b-responsive proinflammatory products
(Figure 5A, 5B and Table S2; see Group 4). These
observations imply that in patients with chronic hepatitis C,
Kupffer cells and/or infiltrating liver macrophages produce IL-1b,
driving a hepatic response that includes the expression of a wide
range of proinflammatory mediators of liver inflammation,
fibrogenesis and disease.
Discussion
Our findings reveal that IL-1b production and hepatic
inflammation in HCV infection are linked and driven through
virus-induced TLR7 and NLRP3 inflammasome signaling in liver
macrophages. These observations support a model of hepatic
inflammation induced by phagocytic uptake of HCV by resident
macrophages/Kupffer cells to trigger IL-1b and drive expression
of proinflammatory cytokines, with IL-1b expression associating
with liver disease in patients with chronic hepatitis C infection
(Figure. 5C). Importantly, macrophages are not a tropic cell for
productive HCV infection. Our studies demonstrate that IL-1b is
stimulated by HCV within hepatic macrophages in a manner that
is independent of actual infection but mediated by phagocytic
uptake of virus. As HCV circulates at high levels with monocytes
in the bloodstream of patients with chronic hepatitis C, it is
noteworthy that the phagocytic uptake of HCV was essential for
induction of inflammasome activity in the macrophage model, and
that undifferentiated monocytes do not phagocytose HCV. The
requirement of phagocytic uptake of HCV for inflammasome
stimulation provides an important checkpoint against systemic IL-
1b production by blood monocytes under conditions of HCV
viremia, thus limiting inflammatory signaling to differentiated
tissue macrophages within the local hepatic environment. Indeed,
phagocytic uptake of HCV and non-self-recognition of viral RNA
is sufficient to trigger IL-1b production from hepatic macrophages.
Although RIG-I-deficient hepatoma cells have been shown to
produce low levels of IL-1b during HCV infection [40], we found
that HCV infection of immune-competent hepatoma cells and
primary hepatocytes does not trigger appreciable production of
IL-1b. These observations reveal an important regulatory feature
of IL-1b production from different cell sources, as hepatocytes
comprise the liver parenchyma and are constantly exposed to
blood-borne microbes like HCV where a wide release of IL-1b
could induce tissue toxicity. Rather, macrophages, including
Kupffer cells, serve a specialized role to sample the local
environment via phagocytosis and selectively render inflammatory
signaling upon pathogen identification, such as TLR7/MyD88-
dependent signaling upon recognition of internalized HCV RNA.
Figure 4. HCV triggers the NLRP3 inflammasome and IL-1b maturation through induction of potassium efflux after macrophage
uptake. (A) Secreted IL-b protein levels (upper panel) and immunoblot analysis of IL-1b (lower panel set) of THP-1 treated with transfection reagent
or transfected with either with full length HCV RNA or polyU/UC RNA or exposed to HCV (moi=0.01). (B) IL-b mRNA expression in THP1 stably
expressing non-targeting control shRNA or shRNA specific to NLRP3 or caspase-1. (C) Immunoblot of caspase-1 and IL-1b in THP1 stably expressing
non-targeting control the indicated shRNA. (D) THP-1 were pre-treated with DMSO (control) or with 6.25, 12.5, 25, 50, 100, 200 mM of potassium
channel inhibitor glybenclamide (Glyben) for 2 hrs followed by mock treatment (M; control) or HCV (moi=0.01) exposure in the presence of glyben
for an additional 1 hr. (E) IL-1b p17 abundance in THP-1 cultured in normal media or in media containing NaCl (100 mM) or KCl (100 mM) for 1 hr
followed by mock-treatment (-) or exposure to HCV (moi=0.01) in the same media for an additional 1 hr.
doi:10.1371/journal.ppat.1003330.g004
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ion flux, both of which trigger the NLRP3 inflammasome during
virus infection, whereas potassium efflux is essential for inflamma-
some signaling by HCV. Our study also reveals that in
macrophages, HCV RNA is engaged by both RIG-I/MAVS-
dependent and TLR7/MyD88-dependent PRR pathways to
induce innate immune (IFN-b) and inflammatory (IL-1b) signal-
ing, respectively. In this respect, the intracellular compartmental-
Figure 5. Macrophage exposure to HCV induces inflammasome signaling of IL-1b and proinflammatory cytokine and chemokine
expression. (A and B) RNA-seq analysis to directly compare the transcription profile of THP1 cells after acute HCV (moi=0.01) exposure for 6 and
16 hours and chronic hepatitis C patient liver staged by mild or severe disease. (A) The Venn diagram shows the number of differentially expressed
genes (.1.5-fold change and FDR, 0.05) that were unique and common to THP-1 cells and chronic hepatitis C patient liver in the most highly
represented KEGG pathways in both datasets, the cytokine-cytokine receptor signaling, and chemokine signaling pathways. (B) Hierarchical
clustering analysis of differentially expressed genes common to both HCV-exposed THP-1 cells and chronic hepatitis C liver. Group-4 genes were
expressed in both THP-1 cells and chronic hepatitis C liver (for full description, see Table S2). Group-4 genes and the expression key are shown at the
right. See Methods for a description of bioinformatics analysis. (C) Model of hepatic inflammatory signaling during HCV infection. Sensing of HCV by
hepatic macrophages triggers the induction of IL-1b and the inflammatory response. HCV-induced inflammasome activation is initiated by
endosomal TLR7 engagement of viral RNA to drive the induction of IL-1b expression via MyD88. In addition, HCV triggers potassium efflux for NLRP3
activation to produce mature IL-1b. Secreted IL-1b induces the expression of a wide-range of proinflammatory mediators and stimulates an
inflammatory response that confers liver disease during chronic infection.
doi:10.1371/journal.ppat.1003330.g005
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components such as HCV RNA to endosomal TLR7 for PRR
engagement [41]. These observations also reflect a key difference
from hepatocytes in which HCV RNA replication products of
infection accumulate at endoplasmic reticulum membrane-associ-
ated cytosolic replication sites independent of endosomal TLRs
but accessible by RIG-I [42], thus amenable to triggering IFN-b
defenses but not IL-1b production. Our RNA transfection
experiments of THP-1 cells deliver HCV RNA into both
endosomal and cytoplasmic compartments for signaling and
reveal the dual potential of the viral RNA to be sensed by both
RIG-I and TLR7 within a compartment-dependent context
within macrophages. Thus, HCV products impart intracellular
signaling and metabolic changes that drive IL-1b production from
macrophages. In the liver, this process is likely mediated by
Kupffer cells, though it may also occur in lymphoid tissue and
other sites exposed to HCV that are populated with macrophages
or other phagocytic cells.
A variety of viruses have been shown to activate the NLRP3
inflammasome, including influenza virus and flaviviruses (West Nile
virus and Japanese encephalitis virus). Like other flaviviruses, HCV
has a positive stranded RNA genome. Whereas NLRP3 inflam-
masome activation and production of IL-1b during infection by
West Nile virus or Japanese encephalitis virus is essential for
proper immune induction and virus control [11,12], NLRP3
activation of IL-1b production by HCV associates markedly with
immunopathogenesis from hepatic inflammation. This relation-
ship is further evident by our RNA-seq analysis, which revealed
that IL-1b and IL-1b-driven genes are associated with severe liver
disease. In infected hepatocytes, HCV subverts innate immune
signaling by targeting and suppressing the RIG-I pathway [21].
Innate immune evasion supports chronic HCV infection and
viremia that lends to macrophage uptake of HCV and signaling by
TLR7 and the NLRP3 inflammasome. The linkage of these
processes of innate immune evasion/persistent viral replication
and viremia/IL-1b production and response thus mediates a cycle
of chronic inflammatory stimulation that underlies liver disease in
HCV infection.
We found that, following virus uptake in macrophages, HCV
proteins are transiently produced but then decay. HCV proteins
have been shown to stimulate ROS accumulation and regulate ion
efflux. Moreover, the HCV p7 protein is a transmembrane cation
channel and a member of the viroporin family whose actions can
drive ion flux that could impart NLRP3 inflammasome activation
during HCV infection [43,44]. Thus, while HCV RNA triggers
inflammasome ‘‘signal one’’ via TLR7, the transient production of
p7 and other HCV proteins may provide stimulus for ‘‘signal
two’’, including potassium flux that induces NLRP3 activation for
IL-1b maturation and secretion. The constant induction of IL-1b
and proinflammatory genes by hepatic macrophages in chronic
hepatitis C patients would then serve to recruit immune cells to the
liver and augment the inflammatory state resulting in liver fibrosis
and cirrhosis (see Figure 5C). Moreover, recent studies show that
HCV uptake by hepatic plasmacytoid dendritic cells and by
Kupffer cells can induce their production and secretion of IFN-b,
thus driving ISG expression and an inflamed state in the local
surrounding hepatocytes [23,26,45]. Whereas HCV infection is
treated with IFN-based therapy [46] and direct-acting antiviral
drugs [47], the local ISG expression from these hepatic myeloid
cells can render a state of innate immune tolerance to attenuate
the antiviral actions of IFN. As a result, IFN treatment is only
partially effective in suppressing HCV [26]. Moreover, it has been
revealed that the IFN response can antagonize inflammasome
signaling [48] while IL-1b can enhance the expression of specific
ISGs to impart increased effectiveness of IFN actions [11]. Thus,
whereas effective antiviral therapy for HCV may actually reduce
liver inflammation [49], this process could involve signaling
crosstalk between IFN and IL-1b that overall enhances IFN
actions [11]. Understanding how such crosstalk imparts restriction
of HCV infection and effective antiviral immune responses should
reveal novel IFN/IL-1b interactions that balance liver inflamma-
tion and immune actions for the control of liver disease.
Interventions that target IL-1b or inflammasome components
[50–52] could thus serve as therapeutic applications to mitigate
HCV-induced hepatic inflammation and disease, particularly
where antiviral agents have failed.
Materials and Methods
Ethics statement
Sera from normal donor or patients with chronic hepatitis C
and liver biopsy tissue from patients with chronic hepatitis C or
controls were obtained with written informed consent and
approval from the human subjects institutional review board
(IRB) of University of Washington, University of Utah, Harvard
Medical School and Singapore institute for clinical sciences.
Patient samples
Chronic hepatitis C patient sera were obtained from patients
infected with HCV genotype-1b who were treatment naı ¨ve and
exhibited liver inflammation with various stages of fibrosis. Liver
biopsies for immune-staining analysis studies were from patients
with chronic HCV-1b infection who had previously undergone
standard of care IFN/ribavirin therapy and were classified as non-
responders with mild liver disease. For RNA-seq studies, patient
liver specimens were analyzed by RNA sequencing and included
normal (unused donor liver; n=6), mild disease chronic hepatitis
C (percutaneous liver biopsies with mild inflammation [Metavir
grade 1–2] and no fibrosis; n=7) and severe disease chronic
hepatitis C (liver explants from patients with chronic hepatitis C
and cirrhosis undergoing liver transplantation; n=6). Biopsy
specimens were from both men and women and were obtained
under IRB approval. All samples were frozen in liquid nitrogen in
RNAase free tubes immediately after collection and stored at
280uC until they were processed for RNA extraction and analysis.
For cytometric analysis, healthy human liver-associated mononu-
clear cells were collected from livers of living donors (n=2) after
portal flush using cold (4uC) preservation solution following
removal of right liver lobes. Collection was performed according
to the standard protocol preceding liver transplantation [53].
Subsequently, liver resident/intrasinusoidal mononuclear cells
were isolated by density gradient centrifugation on Ficoll-
Hypaque. The CD14+ cells (negative for CD3, CD7, CD56,
CD19 and CD20) present in this cell population expressed CD68
and Cd11b to levels similarly to the CD14+ cells purified from
homogenized livers and therefore are defined as ‘‘Kupffer cells’’
[54]. Total purified cells from the liver wash-out were plated in a
96-well round bottom plate, treated with Brefeldin A (10 mg/ml)
and stimulated either with LPS (1 mg/mL), HCV-containing
(MOI 0.1) or mock supernatant for 6 hours. Cells were then
surface stained for CD14 (clone M5E2, BD) and CD16 (clone
3G8, Biolegend) for monocytes, as well as for CD3 (clone HIT3a,
Biolegend), CD7 (clone 4H9, eBioscience), CD56 (clone HCD56,
Biolegend), CD19 (clone HIB19, Biolegend) and CD20 (clone
2H7, Biolegend) for the lineage positive cells, i.e., T-NK-B cells.
Fluorescence and size data from stained cells were acquired using
a Becton Dickenson LSR II flow cytometer and analyzed using
FACS Diva (BD) or FlowJo (Tree star) software.
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Anti-IL-1b was purchased from R&D systems and from Cell
Signaling. Anti-caspase-1 and anti-CD68 antibodies were pur-
chased from Santa Cruz biotechnology. Anti-MyD88 was
purchased from Enzo Life Science. Anti-human CD81 (JS-81)
was purchased from BD pharmingen. Anti-MAVS antibody was
from Abcam, and anti-ASC was from MBL technologies. Anti-
human ISG56 rabbit polyclonal antibody is a gift from Dr. G. Sen.
Human IL-1b, IFNb, NLRP3, TLR7 and GAPDH oligonucleo-
tide PCR primers were purchased from Qiagen (Superarray
bioscience). For HCV protein detection, serum A kindly provided
by Dr. William Lee was used as an immunoblot probe for viral
proteins. Mouse IgG1 (MOPC21), mission lentiviral transduction
particles (Non-targeting, caspase-1, NLRP3, ASC, MAVS, TLR7
or MyD88-specific), adenosine 59-triphsophage (ATP) disodium
salt solution, Phorbol 12-Myristate 13-acetate, LPS, cytochalasin
D, bafilomycin A, diphenyleneiodonium chloride and glybencla-
mide were each purchased from Sigma. Synthetic dsRNA Poly (I):
Poly(C) was from GE Healthcare Life. TransIT-mRNA transfec-
tion kit was from Mirus and IL-1b ELISA kit was from Biolegend.
Cell culture
THP-1 cells were purchased from ATCC and grown in
complete RPMI-1640 medium containing 10% fetal bovine
serum, antibiotics, L-glutamine, pyruvate, and non-essential
amino acid. THP-1 cells were differentiated by treatment with
20–40 nM of PMA overnight at 37C. Huh7 [55], Huh7.5, and
immortalized human hepatocytes (PH5CH8 [56] and IHH- a gift
from Dr. R. Ray, St Louis University, St. Louis, MO.) were grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum, antibiotics, L-glutamine, pyruvate,
non-essential amino acid and Hepes. Monocyte-derived macro-
phages were generated from peripheral blood mononuclear cells
(PBMCs) obtained from healthy individuals under IRB approval.
PBMCs were isolated as described previously [57] and macro-
phages were cultured using plastic adherence as described
elsewhere [58] and cultured in complete RPMI. All cells were
incubated at 37C with 5% CO2.
HCV propagation
An HCV JFH-1 genotype 2a infectious clone was produced
from synthetic cDNA constructed from the published sequence of
original JFH-1 clone [59]. This virus, termed HCV-SJ (Synthetic
JFH1) was then produced directly from in vitro-transcribed RNA
transfected into Huh7.5 cells, and resulting virus was passaged for
culture adaptation. The culture-adapted HCV-SJ will be described
in a subsequent report. For infection studies, HCV-SJ was grown
in Huh7.5 cells, concentrated 1006using Centricon 100,000 MW
cut-off filters (Millipore, Billerica, MA) and titered to determine
focus forming units (ffu)/ml using a Huh7 cell-based FFU assay.
Differentiated THP-1 cells were treated with HCV multiplicity of
infection [moi=0.01–1 based on Huh7 focus forming units (ffu)].
We note that preparations of HCV quantified by the FFU method
contain both infectious and noninfectious particles with the latter
typically represented in 100 to 1000-fold excess over the former
and thus likely contribute to the THP1 cell response to HCV
[21,60,61]. HCV virions were purified under sucrose cushion by
ultracentrifugation. Immortalized primary hepatocytes and hepa-
toma cells were infected with HCV at moi=0.1. Ultraviolet light
inactivation was achieved using the spectrolinker UV crosslinker to
irradiate HCV-containing cell culture media. The media contain-
ing UV-inactivated virus was then used to infect hepatocytes or to
stimulate THP-1 cells.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was extracted from cultured cells using the Qiagen
RNeasy mini kit. qRT-PCR was performed as previously
described [62]. Specific qRT-PCR primers for HCV were: probe
238–267: 59 CCCGCAAGACTGCTAGCCGAGAGTGTTGG
39, forward primer 98–116:59 GAGTGTCGTGCAGCCT-
CCA39, reverse primer 313–294: 59CACTCGCAAGCACCC-
TATCA39, the probe contains 59 6-FAM and 39 TAMRA-sp
modification. RNA amplification was conducted from 50 ng
cDNA conducted in 25 ml reaction mixture in optical 96-well
plates. The reactions were performed under the following
conditions: 30 min at 48C, 1 cycle at 95C for 10 min, 40 cycles
at 95C for 15 seconds and 1 min at 60C and dissociation curve
(95C 1min, 65C 2 min and 65C–95C at 2/sec).
Enzyme-linked Immunosorbent Assay
IL-1b ELISA was run according to the manufacture’s protocol
(Biolegend).
Immunoblot analysis
Cell lysates were recovered from control or HCV-stimulated
samples via cell lysis in RIPA buffer (50 mM Tris-HCl pH 7.4, 1%
Triton-x, 0.25% Na-deoxycholate, 150 mM NaCl, and 1 mM
EDTA). 20–30 mg of protein was subjected to 15% SDS-PAGE
followed by immunoblot assay using the indicated antibodies as
described [30].
Immunohistochemical staining and confocal microscopy
Slide-mounted paraffin-embedded biopsy tissue was deparaffi-
nized, subjected to antigen retrieval, and immunostained with the
indicated antibodies exactly as described previously [63].After
staining, cover slips were mounted on slides using Prolong Gold
mounting medium (Invitrogen). Immunostained tissues were
visualized using a Nikon Eclipse TE2000 inverted microscope
with the Nikon C1 laser scanning confocal module attached to a
10 mW Argon laser, 1 mWHeNe laser, and a 5 mWHeNe laser
emitting light at 477 nM, 543 nM, and 633 nm wavelength,
respectively. Confocal digital images were collected as 0.2 mM
optical sections and were processed using Nikon EZ-C1 Software
v.3.40. Multiple images were collected for each sample analyzed.
The primary antibodies used were anti- IL-1b and anti-CD68.
In vitro transcription of HCV RNA
In vitro transcribed full length HCV RNA (JFH-1), polyU/UC
RNA, and X region RNA was prepared from linearized plasmid
DNA encoding the synthetic JFH1 HCV 2a genome or specific
subgenomic regions using Ambion Mega Script and purified free
of DNA exactly as described [30].
RNA sequencing and transcriptomics analysis
For RNA sequencing (RNA-seq) and associated bioinformatics,
total RNA was purified from cells or clinical biospecimens using
Trizol (Invitrogen, USA) as described previously; and only RNA
specimens yielding a Bioanalyzer (Agilent, USA) RNA integrity
number (RIN) of $8.0 were used [64]. cDNA libraries were
prepared from poly(A) selected mRNA following Illumina RNA-
seq protocols [65]. Single 50 bp RNA-Seq reads were obtained
using Illumina HiSeq 2000 protocols and analyzed following
previous studies [66]. A total of 20–29 million 50 bp reads were
obtained for all chronic hepatitis C and control biospecimens and
16–26 million 50 bp reads for all THP-1 cell samples. Bioinfor-
matics analysis of the RNA-seq data included adjustments for the
depth of sequencing [66]. Sequencing reads were aligned to the
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July 2011 updates, using Novoalign software. The USeqOverdis-
persedRegionScanSeqs (ORSS) application was used to count
reads intersecting exons of each annotated gene and score them
for differential expression in each sample. Scores were controlled
for multiple testing and ranked by false discovery rate (FDR) and
normalized ratio. Genes designated as significantly differentially
expressed had an untransformed FDR of ,0.05 (,5 false positives
per 100 observations) and normalized change of $1.5 fold relative
to controls. Hierarchical cluster analysis to produce heat maps of
differentially expressed genes was done with Cluster 3.0 software
and visualized using Java TreeView [67]. Red=increased
expression and green=reduced expression.
Endotoxin testing
LPS contamination of cell extracts was tested by gel clot assay
using Limulus Amoebocyte Lysate (LAL) Pyrotell from CAPE
COD, Inc. according to manufacturer’s recommendations.
RNA transfection
Differentiated THP-1 cells were transfected using the Mirus
reagent following the company’s protocol (Mirus).
Lentiviral shRNA transduction
Undifferentiated THP-1 cells were transduced with 1–3610‘6
lentiviral particles encoding non-targeting control or gene-specific
shRNA in 48 well plates. 24 hrs post transduction, selection media
was added (RPMI containing puromycin at 1 mg/ml). The cells
were then maintained in selection media. For assessment of
mRNA knockdown, THP1 cells were differentiated with PMA
prior to use in experiments.
Statistical analysis. Statistical analyses were conducted
using unpaired student t-test and GraphPad prism software.
Supporting Information
Figure S1 Validation of chemokine and cytokine gene expres-
sion induced by IL-1b treatment of THP-1 cells. Differentiated
THP-1 cells were treated with 100 ng/ml of recombinant IL-1b
for 6 or 24 hr. RNA was extracted and subjected to qRT-PCR
analysis of gene expression.
(TIF)
Figure S2 (A) Immortalized hepatocytes (IHH and PH5CH8)
and hepatoma Huh7 cells were infected with HCV at moi of 0.1
then IL-1b mRNA expression (upper panel) and protein secretion
(lower panel). (B) Immunoblot examining the expression of
inflammasome components in infected hepatocytes and hepatoma
cells.
(TIF)
Figure S3 Quantification of CD68+ hepatic macrophages/
Kupffer cells determined from healthy donor and chronic hepatitis
C patient liver sections. Liver sections were immuno-stained with
anti-CD68 antibody and analyzed by confocal microscopy. Bars
show average cellnumber and standard error from manual counting
ofat least three independentfieldsfrom tissues ofthree patientseach.
(TIF)
Figure S4 Huh7.5 cells were infected with either viable or UV-
inactivated HCV at moi=0.1. 48 hr later, the cells were
harvested, and RNA and protein were extracted for qRT-PCR
analysis (A) and viral protein abundance by immunoblot assay (B)
antiserum from an HCV patient. Positions of viral proteins are
indicated.
(TIF)
Figure S5 Immunoblot showing viral proteins in HCV-infected
Huh7.5 cells. Cells were infected with HCV-containing superna-
tant (HCV sup) or purified HCV virion from sucrose gradient
ultracentrifugation of infectious supernatant. Cells were infected
with equivalent 0.1 focus forming units (ffu) of either infectious
HCV sup or purified HCV virions for 1 hr. 48 hr later, the cells
were harvested and extracts were subjected to immunoblot
analysis using HCV patient antiserum. Positions of viral proteins
are indicated.
(TIF)
Figure S6 (A) HCV RNA in THP-1 cells. Differentiated THP-1
cells were pre-treated either with anti-CD81 or isotype control for
1 hour at the indicated concentrations. Cells were then washed
and incubated with HCV (moi=0.01 based on Huh7 ffu) in the
presence or absence of anti-CD81 or isotype control antibody at
the same concentration. After 3 hours, cell lysates were harvested,
and RNA was extracted and subjected to qRT-PCR analysis for
determination of HCV RNA copy number as defined by qRT-
PCR of standard HCV RNA template control. (B) Differentiated
THP-1 cells were pretreated with bafilomycin (2.5 mM) or
cytochalasin D (10 mM) for 1 hr and then exposed to HCV in
the presence or absence of continued drug treatment. Cell lysates
were harvested 3 hrs later, and RNA was extracted and subjected
to qRT-PCR analysis for determination of HCV RNA copy
number as defined by qRT-PCR of standard HCV RNA template
control.
(TIF)
Figure S7 Immunoblot assay of MyD88 (A) or MAVS (B)
abundance in THP1 cells expressing non-targeting control shRNA
or shRNA specific to MyD88 (A) or MAVS (B). Cells were infected
with Sendai virus (SenV) for 24 hr prior to harvest. ISG56 and
tubulin expression were respectively monitored as innate immune
response gene and protein loading controls. This immunoblot
confirms the functional knockdown of MAVS as ISG56 is a
MAVS-dependent gene in this context and its production was
completely abolished in shMAVS-expressing cells.
(TIF)
Figure S8 IL-1b and TLR7 expression in THP1 cells expressing
non-targeting control shRNA or shRNA targeting TLR7. (A) Cells
were mock-treated or treated with HCV (moi=0.01 Huh7 ffu) for
6 hr and RNA extracted for qRT-PCR analysis of IL-1b mRNA
expression. (B) TLR7 mRNA levels were assessed 6 hr after
transfection reagent alone or HCV polyU/UC RNA transfection.
(TIF)
Figure S9 Immunoblot showing the levels of caspase-1 (A),
NLRP3 (B) and ASC (C) in cells expressing specific knockdown
shRNA in THP-1 cells transduced with lentiviral particles as
compared to non-targeting control.
(TIF)
Figure S10 Differentiated THP-1 cells were, from left to right,
mock treated, treated with HCV (moi=0.01 based on Huh7 ffu)
or pretreated with 0.3,0.6, 1.25, 2.5, 5, 10, 20, 40, 80 mM
Diphenyleneiodonium chloride (DPI) for 1 hr followed by HCV
treatment. 3 hr later cells were harvested and extracts subjected to
immunoblot analysis for mature IL-1b and tubulin.
(TIF)
Table S1 Differentially expressed genes in liver biopsy speci-
mens from chronic hepatitis C patients with mild (no fibrosis) and
severe (cirrhosis) liver disease represented in (Figure 1A) Group-1
shows genes reduced in expression or ‘‘down-regulated’’ in
association with HCV infection compared to control liver;
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in HCV infection (mild and severe disease) compared to control
liver; group-3 shows genes highly up-regulated in association with
severe disease only compared to control liver; group-4 shows genes
highly down-regulated in mild but not in severe disease patient
livers.
(TIF)
Table S2 Differentially expressed genes in chronic hepatitis C
liver specimens with mild (no fibrosis) and severe (cirrhosis) disease
or in THP-1 cells exposed to HCV represented in (Figure 5B).
Group-1 shows genes up-regulated in HCV-exposed THP-1 cells
only, as compared to mock-treated THP1 control cells; group-2
shows genes expressed in association with severe liver disease only
but not in THP-1 cells; group-3 shows genes down-regulated in
both hepatitis C liver and HCV-treated THP-1 cells; group-4
shows genes commonly expressed in both hepatitis C liver and
HCV-treated THP-1 cells. Gene expression, as measured by
RNA-seq analysis, in hepatitis C liver specimens was compared
with control liver specimens. Gene expression in HCV-treated
THP1 cells was compared with mock-treated THP1 cells.
(TIF)
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